pgen-20220331
false2022Q1000135609012/31http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006MemberP5DP1Y00013560902022-01-012022-03-3100013560902022-04-30xbrli:shares00013560902022-03-31iso4217:USD00013560902021-12-310001356090pgen:RelatedPartiesAggregatedMember2021-12-310001356090pgen:RelatedPartiesAggregatedMember2022-03-31iso4217:USDxbrli:shares0001356090us-gaap:CollaborativeArrangementMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090us-gaap:CollaborativeArrangementMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-03-310001356090us-gaap:ProductMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090us-gaap:ProductMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-03-310001356090us-gaap:ServiceMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090us-gaap:ServiceMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-03-310001356090pgen:OtherMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090pgen:OtherMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-03-310001356090us-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090us-gaap:SegmentContinuingOperationsMember2021-01-012021-03-3100013560902021-01-012021-03-310001356090us-gaap:CommonStockMember2021-12-310001356090us-gaap:AdditionalPaidInCapitalMember2021-12-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001356090us-gaap:RetainedEarningsMember2021-12-310001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2021-12-310001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001356090us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001356090us-gaap:CommonStockMember2022-01-012022-03-310001356090us-gaap:RetainedEarningsMember2022-01-012022-03-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001356090us-gaap:CommonStockMember2022-03-310001356090us-gaap:AdditionalPaidInCapitalMember2022-03-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001356090us-gaap:RetainedEarningsMember2022-03-310001356090us-gaap:CommonStockMember2020-12-310001356090us-gaap:AdditionalPaidInCapitalMember2020-12-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001356090us-gaap:RetainedEarningsMember2020-12-3100013560902020-12-310001356090us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001356090us-gaap:CommonStockMember2021-01-012021-03-310001356090us-gaap:RetainedEarningsMember2021-01-012021-03-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001356090us-gaap:CommonStockMember2021-03-310001356090us-gaap:AdditionalPaidInCapitalMember2021-03-310001356090us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001356090us-gaap:RetainedEarningsMember2021-03-3100013560902021-03-310001356090us-gaap:ConvertibleDebtMember2022-01-012022-03-310001356090us-gaap:ConvertibleDebtMember2021-01-012021-03-310001356090us-gaap:StockOptionMember2022-01-012022-03-310001356090us-gaap:StockOptionMember2021-01-012021-03-310001356090us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001356090us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001356090us-gaap:WarrantMember2022-01-012022-03-310001356090us-gaap:WarrantMember2021-01-012021-03-310001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006RetrospectiveMember2022-01-010001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:AccountingStandardsUpdate202006RetrospectiveMember2022-01-010001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006RetrospectiveMemberus-gaap:RetainedEarningsMember2022-01-010001356090srt:CumulativeEffectPeriodOfAdoptionAdjustmentMembersrt:ScenarioForecastMemberus-gaap:AccountingStandardsUpdate202006RetrospectiveMember2022-01-012022-12-310001356090us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberpgen:MBPTitanMember2022-01-012022-03-310001356090us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMemberpgen:MBPTitanMember2021-01-012021-03-310001356090pgen:IntrexonEnergyPartnersMemberus-gaap:CollaborativeArrangementMember2014-03-012014-03-310001356090pgen:IntrexonEnergyPartnersMember2014-03-31xbrli:pure0001356090us-gaap:InvestorMemberpgen:IntrexonEnergyPartnersMember2014-03-012014-03-310001356090us-gaap:InvestorMemberpgen:IntrexonEnergyPartnersMember2014-03-310001356090pgen:IntrexonEnergyPartnersMember2022-03-31pgen:board_seat0001356090pgen:OtherAccruedLiabilitiesMemberpgen:IntrexonEnergyPartnersMember2022-03-310001356090pgen:OtherAccruedLiabilitiesMemberpgen:IntrexonEnergyPartnersMember2021-12-310001356090pgen:IntrexonEnergyPartnersIILLCMemberus-gaap:CollaborativeArrangementMember2015-12-012015-12-310001356090pgen:IntrexonEnergyPartnersIILLCMember2015-12-310001356090us-gaap:InvestorMemberpgen:IntrexonEnergyPartnersIILLCMember2015-12-012015-12-310001356090us-gaap:InvestorMemberpgen:IntrexonEnergyPartnersIILLCMember2015-12-310001356090pgen:IntrexonEnergyPartnersIILLCMemberpgen:AllInvestorsMember2015-12-012015-12-310001356090pgen:IntrexonEnergyPartnersIILLCMember2022-03-310001356090pgen:OtherAccruedLiabilitiesMemberpgen:IntrexonEnergyPartnersIILLCMember2021-12-310001356090pgen:OtherAccruedLiabilitiesMemberpgen:IntrexonEnergyPartnersIILLCMember2022-03-310001356090pgen:CastleCreekBiosciencesIncMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310001356090pgen:CastleCreekBiosciencesIncMemberus-gaap:CollaborativeArrangementMember2021-01-012021-03-310001356090us-gaap:CollaborativeArrangementMemberpgen:OtherMember2022-01-012022-03-310001356090us-gaap:CollaborativeArrangementMemberpgen:OtherMember2021-01-012021-03-310001356090us-gaap:CollaborativeArrangementMember2022-01-012022-03-310001356090us-gaap:CollaborativeArrangementMember2021-01-012021-03-310001356090pgen:UpfrontAndMilestonePaymentsMember2022-01-012022-03-310001356090pgen:UpfrontAndMilestonePaymentsMember2021-01-012021-03-310001356090pgen:IntrexonEnergyPartnersLLAndIntrexonEnergyPartnersIILLCMember2022-03-310001356090us-gaap:CollaborativeArrangementMember2022-03-310001356090us-gaap:CollaborativeArrangementMember2021-12-310001356090pgen:PrepaidProductAndServiceRevenuesMember2022-03-310001356090pgen:PrepaidProductAndServiceRevenuesMember2021-12-310001356090pgen:DeferredRevenueOtherMember2022-03-310001356090pgen:DeferredRevenueOtherMember2021-12-310001356090us-gaap:USGovernmentDebtSecuritiesMember2022-03-310001356090us-gaap:CertificatesOfDepositMember2022-03-310001356090us-gaap:USGovernmentDebtSecuritiesMember2021-12-310001356090us-gaap:CertificatesOfDepositMember2021-12-310001356090us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2022-03-310001356090us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMember2022-03-310001356090us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMember2022-03-310001356090us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2022-03-310001356090us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2022-03-310001356090us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2022-03-310001356090us-gaap:FairValueInputsLevel1Member2022-03-310001356090us-gaap:FairValueInputsLevel2Member2022-03-310001356090us-gaap:FairValueInputsLevel3Member2022-03-310001356090us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMember2021-12-310001356090us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMember2021-12-310001356090us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMember2021-12-310001356090us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2021-12-310001356090us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2021-12-310001356090us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2021-12-310001356090us-gaap:FairValueInputsLevel1Member2021-12-310001356090us-gaap:FairValueInputsLevel2Member2021-12-310001356090us-gaap:FairValueInputsLevel3Member2021-12-310001356090pgen:A3.5ConvertibleNotesDue2023Member2022-03-310001356090pgen:A3.5ConvertibleNotesDue2023Member2021-12-310001356090pgen:SuppliesEmbryosAndOtherProductionMaterialsMember2022-03-310001356090pgen:SuppliesEmbryosAndOtherProductionMaterialsMember2021-12-310001356090pgen:WorkInProcessMember2022-03-310001356090pgen:WorkInProcessMember2021-12-310001356090pgen:LivestockMember2022-03-310001356090pgen:LivestockMember2021-12-310001356090pgen:FeedMember2022-03-310001356090pgen:FeedMember2021-12-31pgen:reporting_unit0001356090us-gaap:IntellectualPropertyMember2022-03-310001356090us-gaap:CustomerRelationshipsMember2022-03-310001356090us-gaap:TrademarksMember2022-03-310001356090us-gaap:IntellectualPropertyMember2021-12-310001356090us-gaap:CustomerRelationshipsMember2021-12-310001356090us-gaap:TrademarksMember2021-12-310001356090pgen:FirstNationalBankofOmahaMemberus-gaap:RevolvingCreditFacilityMemberpgen:TransOvaGeneticsLcMember2022-03-310001356090srt:MinimumMemberpgen:FirstNationalBankofOmahaMemberus-gaap:RevolvingCreditFacilityMemberpgen:TransOvaGeneticsLcMember2022-03-310001356090pgen:FirstNationalBankofOmahaMemberus-gaap:RevolvingCreditFacilityMemberpgen:TransOvaGeneticsLcMember2021-12-310001356090pgen:ExemplarGeneticsLLCMemberpgen:AmericanStateBankMemberus-gaap:RevolvingCreditFacilityMember2022-03-310001356090pgen:ExemplarGeneticsLLCMemberpgen:AmericanStateBankMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001356090us-gaap:ConvertibleDebtMember2022-03-310001356090us-gaap:ConvertibleDebtMember2021-12-310001356090us-gaap:NotesPayableToBanksMember2022-03-310001356090us-gaap:NotesPayableToBanksMember2021-12-310001356090pgen:OtherLongTermDebtMember2022-03-310001356090pgen:OtherLongTermDebtMember2021-12-310001356090pgen:A3.5ConvertibleNotesDue2023Member2018-07-310001356090pgen:A3.5ConvertibleNotesDue2023Member2018-07-012018-07-310001356090srt:MinimumMemberpgen:A3.5ConvertibleNotesDue2023Member2018-07-012018-07-31pgen:day0001356090pgen:A3.5ConvertibleNotesDue2023Membersrt:MaximumMember2018-07-012018-07-310001356090pgen:A3.5ConvertibleNotesDue2023Member2022-01-012022-03-310001356090pgen:A3.5ConvertibleNotesDue2023Member2021-01-012021-03-310001356090us-gaap:NotesPayableToBanksMemberpgen:AmericanStateBankMemberpgen:TransOvaGeneticsLcMember2022-03-310001356090us-gaap:NotesPayableToBanksMemberpgen:AmericanStateBankMemberpgen:TransOvaGeneticsLcMember2022-01-012022-03-310001356090us-gaap:DomesticCountryMember2022-01-012022-03-310001356090us-gaap:DomesticCountryMember2021-01-012021-03-310001356090us-gaap:ForeignCountryMemberus-gaap:SegmentContinuingOperationsMember2022-01-012022-03-310001356090us-gaap:ForeignCountryMemberus-gaap:SegmentContinuingOperationsMember2021-01-012021-03-310001356090us-gaap:DomesticCountryMember2022-03-310001356090pgen:GeneratedAfter2017Member2022-03-310001356090us-gaap:ForeignCountryMember2022-03-3100013560902021-01-012021-01-3100013560902018-07-012018-07-3100013560902018-07-310001356090us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310001356090us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001356090us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001356090us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001356090pgen:CostOfProductsMember2022-01-012022-03-310001356090pgen:CostOfProductsMember2021-01-012021-03-310001356090pgen:CostOfServicesMember2022-01-012022-03-310001356090pgen:CostOfServicesMember2021-01-012021-03-310001356090us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001356090us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001356090us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001356090us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310001356090pgen:PrecigenStockOptionPlan2008PlanMember2022-03-310001356090pgen:PrecigenStockOptionPlan2013PlanMember2022-03-310001356090us-gaap:SubsequentEventMemberpgen:PrecigenStockOptionPlan2013PlanMember2022-04-300001356090pgen:PrecigenStockOptionPlan2019PlanMember2022-03-310001356090us-gaap:SubsequentEventMemberpgen:PrecigenStockOptionPlan2019PlanMember2022-04-300001356090pgen:PrecigenStockOptionPlanMember2021-12-310001356090pgen:PrecigenStockOptionPlanMember2021-01-012021-12-310001356090pgen:PrecigenStockOptionPlanMember2022-01-012022-03-310001356090pgen:PrecigenStockOptionPlanMember2022-03-310001356090pgen:ExecutiveChairmanMember2020-07-012020-09-300001356090pgen:ExecutiveChairmanMember2020-07-012020-09-300001356090pgen:ExecutiveChairmanMember2020-09-012020-09-300001356090us-gaap:EmployeeStockOptionMemberpgen:ExecutiveChairmanMember2020-09-012020-09-300001356090us-gaap:RestrictedStockUnitsRSUMemberpgen:ExecutiveChairmanMember2020-09-012020-09-300001356090us-gaap:SellingGeneralAndAdministrativeExpensesMemberpgen:ExecutiveChairmanMember2022-01-012022-03-310001356090us-gaap:SellingGeneralAndAdministrativeExpensesMemberpgen:ExecutiveChairmanMember2021-01-012021-03-310001356090srt:MinimumMember2022-03-310001356090srt:MaximumMember2022-03-310001356090pgen:XYLLCMemberpgen:LicensingAndPatentInfringementSuitMember2020-12-012020-12-01pgen:claim0001356090pgen:XYLLCMemberpgen:LicensingAndPatentInfringementSuitMember2020-11-300001356090pgen:XYLLCMemberpgen:LicensingAndPatentInfringementSuitMember2016-12-310001356090pgen:XYLLCMemberpgen:LicensingAndPatentInfringementSuitMember2022-03-31pgen:patent0001356090pgen:MethaneBioconversionPlatformDisclosuresMemberpgen:SecuritiesAndExchangeCommissionMember2020-09-012020-09-300001356090pgen:IntrexonEnergyPartnersMember2022-03-012022-03-310001356090pgen:IntrexonEnergyPartnersIILLCMember2022-03-012022-03-310001356090pgen:IntrexonEnergyPartnersMemberpgen:IntrexonEnergyPartnersLLAndIntrexonEnergyPartnersIILLCMember2022-03-012022-03-310001356090pgen:IntrexonEnergyPartnersLLAndIntrexonEnergyPartnersIILLCMemberpgen:IntrexonEnergyPartnersIILLCMember2022-03-012022-03-310001356090pgen:IntrexonEnergyPartnersMember2022-03-310001356090pgen:IntrexonEnergyPartnersIILLCMember2022-03-310001356090pgen:ThirdSecurityMemberpgen:ExecutiveChairmanMember2022-03-310001356090pgen:ThirdSecurityMember2022-01-012022-03-310001356090pgen:ThirdSecurityMember2021-01-012021-03-310001356090pgen:BiopharmaceuticalsSegmentMember2022-01-012022-03-310001356090pgen:BiopharmaceuticalsSegmentMember2021-01-012021-03-310001356090pgen:ExemplarSegmentMember2022-01-012022-03-310001356090pgen:ExemplarSegmentMember2021-01-012021-03-310001356090pgen:TransOvaSegmentMember2022-01-012022-03-310001356090pgen:TransOvaSegmentMember2021-01-012021-03-310001356090pgen:ReportableSegmentsMember2022-01-012022-03-310001356090pgen:ReportableSegmentsMember2021-01-012021-03-310001356090us-gaap:OperatingSegmentsMember2022-01-012022-03-310001356090us-gaap:OperatingSegmentsMember2021-01-012021-03-310001356090us-gaap:OperatingSegmentsMemberpgen:UpfrontAndMilestonePaymentsMember2022-01-012022-03-310001356090us-gaap:OperatingSegmentsMemberpgen:UpfrontAndMilestonePaymentsMember2021-01-012021-03-310001356090pgen:CorporateAndReconcilingItemsMember2022-01-012022-03-310001356090pgen:CorporateAndReconcilingItemsMember2021-01-012021-03-310001356090us-gaap:CorporateNonSegmentMember2022-01-012022-03-310001356090us-gaap:CorporateNonSegmentMember2021-01-012021-03-310001356090us-gaap:IntersegmentEliminationMember2022-01-012022-03-310001356090us-gaap:IntersegmentEliminationMember2021-01-012021-03-310001356090pgen:BiopharmaceuticalsSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001356090pgen:ExemplarSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001356090us-gaap:OperatingSegmentsMemberpgen:TransOvaSegmentMember2022-01-012022-03-310001356090us-gaap:IntersegmentEliminationMemberpgen:BiopharmaceuticalsSegmentMember2022-01-012022-03-310001356090pgen:ExemplarSegmentMemberus-gaap:IntersegmentEliminationMember2022-01-012022-03-310001356090us-gaap:IntersegmentEliminationMemberpgen:TransOvaSegmentMember2022-01-012022-03-310001356090pgen:BiopharmaceuticalsSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001356090pgen:ExemplarSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-03-310001356090us-gaap:OperatingSegmentsMemberpgen:TransOvaSegmentMember2021-01-012021-03-310001356090us-gaap:IntersegmentEliminationMemberpgen:BiopharmaceuticalsSegmentMember2021-01-012021-03-310001356090pgen:ExemplarSegmentMemberus-gaap:IntersegmentEliminationMember2021-01-012021-03-310001356090us-gaap:IntersegmentEliminationMemberpgen:TransOvaSegmentMember2021-01-012021-03-310001356090pgen:EliminationsAndReconcilingItemsMember2022-01-012022-03-310001356090pgen:EliminationsAndReconcilingItemsMember2021-01-012021-03-310001356090us-gaap:NonUsMember2022-03-310001356090us-gaap:NonUsMember2021-12-310001356090us-gaap:NonUsMember2022-01-012022-03-310001356090us-gaap:NonUsMember2021-01-012021-03-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     .
Commission File Number: 001-36042
 PRECIGEN, INC.
(Exact name of registrant as specified in its charter)
Virginia 26-0084895
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification Number)
20374 Seneca Meadows Parkway 
Germantown,Maryland 20876
(Address of principal executive offices) (Zip Code)
(301) 556-9900
(Registrant's telephone number, including area code) 
N/A
(Former name, former address and former fiscal year, if changed since last report) 
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PGEN Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer  Accelerated filer 
Non-accelerated filer  Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of April 30, 2022, 207,693,277 shares of common stock, no par value per share, were issued and outstanding.


Table of Contents
PRECIGEN, INC.
FORM 10-Q
TABLE OF CONTENTS
 
Item No. Page
1.
2.
3.
4.
1.
1A.
2.
3.
4.
5.
6.
Intrexon®, Trans Ova Genetics®, Progentus®, UltraCAR-T®, RheoSwitch®, UltraVector®, RTS®, and RheoSwitch Therapeutic System® are our and/or our affiliates' registered trademarks in the United States and ActoBiotics™, GenVec™, Precigen™, AdenoVerse™, ActoBio Therapeutics™, UltraPorator™, AttSite™, and Precigen Therapeutics™ are our and/or our affiliates' common law trademarks in the United States. This Quarterly Report on Form 10-Q, or Quarterly Report, and the information incorporated herein by reference contain references to trademarks, service marks, and trade names owned by us or other companies. Solely for convenience, trademarks, service marks, and trade names referred to in this Quarterly Report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks, and trade names. We do not intend our use or display of other companies' trade names, service marks, or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names, and service marks appearing in this Quarterly Report are the property of their respective owners. Unless the context requires otherwise, references in this Quarterly Report to "Precigen", "we", "us", and "our" refer to Precigen, Inc.
2

Table of Contents

Special Note Regarding Forward-Looking Statements
This Quarterly Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report, including statements regarding our strategy; future events, including their outcome or timing; future operations; future financial position; future revenue; projected costs; prospects; plans; objectives of management; and expected market growth, are forward-looking statements. The words "aim", "anticipate", "assume", "believe", "continue", "could", "due", "estimate", "expect", "intend", "may", "plan", "positioned", "potential", "predict", "project", "seek", "should", "target", "will", "would", and the negatives of these terms or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements may relate to, among other things: (i) the impact of the COVID-19 pandemic on our clinical trials, businesses, operating results, cash flows, and/or financial condition; (ii) the timeliness of regulatory approvals; (iii) our strategy and overall approach to our business model, our efforts to realign our business, and our ability to exercise more control and ownership over the development process and commercialization path; (iv) our ability to successfully enter new markets or develop additional product candidates, including the expected timing and results of investigational studies and preclinical and clinical trials, including any delays or potential delays as a result of the COVID-19 pandemic, whether with our collaborators or independently; (v) our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers; (vi) our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future; (vii) our ability to hold or generate significant operating capital, including through partnering, asset sales, and operating cost reductions; (viii) actual or anticipated variations in our operating results; (ix) actual or anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (x) our cash position; (xi) market conditions in our industry; (xii) the volatility of our stock price; (xiii) the ability, and the ability of our collaborators, to protect our intellectual property and other proprietary rights and technologies; (xiv) our ability, and the ability of our collaborators, to adapt to changes in laws or regulations or policies, including federal, state, and local government responses to the COVID-19 pandemic; (xv) outcomes of pending and future litigation; (xvi) the rate and degree of market acceptance of any products developed by us, our subsidiaries, collaborations, or joint ventures, or JVs, and competition from existing technologies and products or new technologies and products that may emerge; (xvii) our ability to retain and recruit key personnel; (xviii) expectations related to the use of proceeds from public offerings and other financing efforts; (xix) estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; and (xx) the effects, duration, and severity of the ongoing COVID-19 pandemic and the actions we and others have taken or may take in response.
Forward-looking statements are based on our beliefs, assumptions, and expectations of our future performance, and may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report.
We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in Part II, Item 1A, "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, JVs, or investments that we may make.
You should read this Quarterly Report, the documents that we reference in this Quarterly Report, our Annual Report on Form 10-K for the year ended December 31, 2021, the other reports we have filed with the Securities and Exchange Commission, or SEC, and the documents that we have filed as exhibits to our filings with the SEC completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
3

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Precigen, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
(Amounts in thousands, except share data)March 31,
2022
December 31,
2021
Assets
Current assets
Cash and cash equivalents$40,321 $42,920 
Short-term investments71,821 72,240 
Receivables
Trade, less allowance for credit losses of $4,631 and $4,288 as of March 31, 2022 and December 31, 2021, respectively
24,308 20,832 
Related parties, less allowance for credit losses of $1,509 as of March 31, 2022 and December 31, 2021
15 73 
Other543 566 
Inventory12,730 13,261 
Prepaid expenses and other5,199 6,736 
Total current assets154,937 156,628 
Long-term investments29,914 48,562 
Property, plant and equipment, net33,583 34,315 
Intangible assets, net51,427 54,115 
Goodwill53,613 54,148 
Right-of-use assets10,963 10,900 
Other assets1,131 1,188 
Total assets$335,568 $359,856 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited) 
(Amounts in thousands, except share data)March 31,
2022
December 31,
2021
Liabilities and Shareholders' Equity
Current liabilities
Accounts payable$4,415 $5,405 
Accrued compensation and benefits6,052 11,223 
Other accrued liabilities10,494 11,595 
Deferred revenue2,669 4,442 
Current portion of long-term debt355 402 
Current portion of lease liabilities1,590 1,551 
Related party payables26 27 
Total current liabilities25,601 34,645 
Long-term debt, net of current portion201,112 182,749 
Deferred revenue, net of current portion, including $21,205 from related parties as of March 31, 2022 and December 31, 2021
23,023 23,023 
Lease liabilities, net of current portion9,508 9,502 
Deferred tax liabilities2,438 2,539 
Other long-term liabilities50 50 
Total liabilities261,732 252,508 
Commitments and contingencies (Note 16)
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 207,693,277 shares and 206,739,874 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
  
Additional paid-in capital1,991,670 2,022,701 
Accumulated deficit(1,916,135)(1,915,556)
Accumulated other comprehensive (loss) income(1,699)203 
Total shareholders' equity73,836 107,348 
Total liabilities and shareholders' equity$335,568 $359,856 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)

(Amounts in thousands, except share and per share data)Three Months Ended 
 March 31,
20222021
Revenues
Collaboration and licensing revenues$ $66 
Product revenues8,724 6,381 
Service revenues23,209 17,931 
Other revenues88 133 
Total revenues32,021 24,511 
Operating Expenses
Cost of products7,510 5,574 
Cost of services9,589 7,402 
Research and development12,760 10,521 
Selling, general and administrative19,576 18,702 
Impairment of goodwill482  
Total operating expenses49,917 42,199 
Operating loss(17,896)(17,688)
Other Expense, Net
Interest expense(2,069)(4,539)
Interest income434 392 
Other income (expense), net223 (58)
Total other expense, net(1,412)(4,205)
Equity in net loss of affiliates(1)(3)
Loss from continuing operations before income taxes(19,309)(21,896)
Income tax benefit58 52 
Loss from continuing operations(19,251)(21,844)
Income from discontinued operations, net of income taxes 4,526 
Net loss$(19,251)$(17,318)
Net Loss per Share
Net loss from continuing operations per share, basic and diluted$(0.10)$(0.11)
Net income from discontinued operations per share, basic and diluted 0.02 
Net loss per share, basic and diluted$(0.10)$(0.09)
Weighted average shares outstanding, basic and diluted199,629,218 193,499,546 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
 
 Three Months Ended 
 March 31,
(Amounts in thousands)20222021
Net loss$(19,251)$(17,318)
Other comprehensive loss:
Unrealized loss on investments(802)(48)
Loss on foreign currency translation adjustments(1,100)(2,203)
Comprehensive loss$(21,153)$(19,569)
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)
 
(Amounts in thousands, except share data)Common StockAdditional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Shareholders'
Equity
SharesAmount
Balances at December 31, 2021206,739,874 $ $2,022,701 $203 $(1,915,556)$107,348 
Cumulative effect of adoption of ASU 2020-06— — (36,868)— 18,672 (18,196)
Stock-based compensation expense— — 3,562 — — 3,562 
Shares issued upon vesting of restricted stock units and for exercises of stock options354,089 — 1 — — 1 
Shares issued for accrued compensation315,327 — 1,698 — — 1,698 
Shares issued as payment for services283,987 — 576 — — 576 
Net loss— — — — (19,251)(19,251)
Other comprehensive loss— — — (1,902)— (1,902)
Balances at March 31, 2022207,693,277 $ $1,991,670 $(1,699)$(1,916,135)$73,836 
(Amounts in thousands, except share data)Common StockAdditional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Shareholders'
Equity
SharesAmount
Balances at December 31, 2020187,663,207 $ $1,886,567 $3,997 $(1,823,390)$67,174 
Stock-based compensation expense— — 5,415 — — 5,415 
Shares issued upon vesting of restricted stock units and for exercises of stock options1,426,157 — 153 — — 153 
Shares issued as payment for services74,771 — 577 — — 577 
Shares issued in public offerings, net of issuance costs17,250,000 — 121,045 — — 121,045 
Net loss— — — — (17,318)(17,318)
Other comprehensive loss— — — (2,251)— (2,251)
Balances at March 31, 2021206,414,135 $ $2,013,757 $1,746 $(1,840,708)$174,795 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Three Months Ended 
 March 31,
(Amounts in thousands)20222021
Cash flows from operating activities
Net loss$(19,251)$(17,318)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization3,292 3,523 
Loss (gain) on disposals of assets, net125 (343)
Impairment of goodwill482  
Amortization of premiums on investments, net265 57 
Equity in net loss of affiliates1 3 
Stock-based compensation expense3,562 5,415 
Shares issued as payment for services576 577 
Provision for credit losses334 162 
Accretion of debt discount and amortization of deferred financing costs284 2,751 
Deferred income taxes(58)(56)
Noncash gain on termination of operating leases (4,602)
Other noncash items 1 
Changes in operating assets and liabilities:
Receivables:
Trade(3,696)(4,949)
Related parties58 7 
Other21 (279)
Inventory531 721 
Prepaid expenses and other1,571 844 
Other assets42 95 
Accounts payable(588)(189)
Accrued compensation and benefits(3,462)(1,893)
Other accrued liabilities(1,086)(2,216)
Deferred revenue(1,767)1,054 
Lease liabilities(18)218 
Related party payables(1)33 
Net cash used in operating activities(18,783)(16,384)
The accompanying notes are an integral part of these condensed consolidated financial statements.
9

Table of Contents
Precigen, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)

 Three Months Ended 
 March 31,
(Amounts in thousands)20222021
Cash flows from investing activities
Purchases of investments$ $(174,221)
Sales and maturities of investments18,000 40,500 
Purchases of property, plant and equipment(1,579)(1,014)
Proceeds from sale of assets147 1,944 
Proceeds from repayment of notes receivable 3,689 
Net cash provided by (used in) investing activities16,568 (129,102)
Cash flows from financing activities
Proceeds from issuance of shares, net of issuance costs 121,045 
Payments of long-term debt(164)(116)
Proceeds from stock option exercises1 111 
Net cash (used in) provided by financing activities(163)121,040 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(230)(11)
Net decrease in cash, cash equivalents, and restricted cash(2,608)(24,457)
Cash, cash equivalents, and restricted cash
Beginning of period43,343 52,250 
End of period$40,735 $27,793 
Supplemental disclosure of cash flow information
Cash paid during the period for interest$3,535 $3,539 
Cash paid during the period for income taxes 4 
Significant noncash activities
Accrued compensation paid in equity awards$1,698 $ 
Purchases of property and equipment included in accounts payable and other accrued liabilities251 255 
Proceeds from sale of assets included in accounts receivable132 23 
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of March 31, 2022 and December 31, 2021 as shown above:
March 31,
2022
December 31,
2021
Cash and cash equivalents$40,321 $42,920 
Restricted cash included in other assets414 423 
Cash, cash equivalents, and restricted cash$40,735 $43,343 
The accompanying notes are an integral part of these condensed consolidated financial statements.
10

Table of Contents
Precigen, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
(Amounts in thousands, except share and per share data)
1. Organization
Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen operates through the following subsidiaries:
PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland.
Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium.
Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa.
Trans Ova Genetics, L.C., including its wholly owned subsidiary Progentus, L.C., are providers of reproductive technologies, including services and products sold to cattle breeders and other producers and are hereinafter collectively referred to as "Trans Ova." Trans Ova is a wholly owned subsidiary with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin.
Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform ("MBP") assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and had substantially completed the wind down by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion.
Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company."
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of March 31, 2022 and results of operations and cash flows for the interim periods ended March 31, 2022 and 2021. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.
11

Table of Contents
The accompanying condensed consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.
Liquidity
Management believes that existing liquid assets as of March 31, 2022 will allow the Company to continue its operations for at least a year from the issuance date of these condensed consolidated financial statements. These condensed consolidated financial statements are presented in United States dollars. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of therapeutic product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development, and clinical manufacturing of its and its collaborators' therapeutic product candidates. Additionally, the accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the three months ended March 31, 2022, the Company incurred a net loss of $19,251 and, as of March 31, 2022, had an accumulated deficit of $1,916,135. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development (which could occur through debt or equity issuances, sales or partnerships of non-core assets, corroborations or licensing of core or non-core assets, or other transactions), adequately satisfy or renegotiate long-term debt obligations, obtain regulatory approval of its therapeutic product candidates, successfully commercialize its therapeutic product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.
Risks and Uncertainties
COVID-19 has had and continues to have an extensive impact on the global health and economic environments. Furthermore, there is uncertainty regarding the duration and severity of the ongoing pandemic, and the Company could experience delays or other pandemic-related events that may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future.
The Company is closely monitoring the impact of COVID-19 on all aspects of its businesses. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses.
See Note 3 for further discussion of the impact of COVID-19 on MBP Titan.
Equity Method Investments
The Company accounts for its investments in each of its joint ventures ("JVs") using the equity method of accounting based upon relative ownership interest. See additional discussion related to certain of the Company's JVs in Note 4.
Variable Interest Entities
As of March 31, 2022 and December 31, 2021, the Company determined that its JVs were variable interest entities ("VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. As of March 31, 2022 and December 31, 2021, the Company had no risk of loss related to the identified VIEs. See Note 4 for discussion of the Company's future funding commitments for its significant JVs.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the
12

Table of Contents
calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
The following potentially dilutive securities as of March 31, 2022 and 2021, have been excluded from the above computations of diluted weighted average shares outstanding for the three months then ended as they would have been anti-dilutive:
March 31,
20222021
Convertible debt11,732,440 11,732,440 
Options16,034,553 11,451,614 
Restricted stock units1,185,205 790,364 
Warrants121,888 133,264 
Total29,074,086 24,107,682 
Segment Information
The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. Starting in 2021, the financial information regularly reviewed by the CODM was revised and the operating segments, which were determined to be operating and reportable segments, were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. The Biopharmaceuticals reportable segment is primarily comprised of the Company's legal entities of PGEN Therapeutics and ActoBio. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, Exemplar, and Trans Ova. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, gain or loss on disposals of assets, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 18 for further discussion of the Company's segments.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncements
In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ("ASU 2020-06"). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments.
We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported long-term debt outstanding, net of current portion, of $18,196, a decrease to our additional paid-in capital of $36,868, and a corresponding cumulative-effect reduction to our opening accumulated deficit of $18,672. The adoption of ASU 2020-06 is expected to reduce non-cash interest expense related to existing convertible debt outstanding by approximately $11,800 for the year ending December 31, 2022, and did not have an impact on our consolidated cash flows. The use of the if-converted method did not have an impact on our overall earnings per share calculation.
13

Table of Contents
Recently Issued Accounting Pronouncements Not Yet Adopted
There are no accounting standards which have not yet been adopted that are expected to have a significant impact on our financial statements and related disclosures.
3. Discontinued Operations
Where applicable, the notes to the accompanying condensed consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations based on the discontinued operations summarized below.
MBP Titan
As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially completed by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges that the Company commenced in 2020. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are reclassified and presented as discontinued operations in the accompanying condensed consolidated financial statements for all periods.
The January 2021 sale of property and equipment resulted in a gain on disposal of assets of $464, which is included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2021. In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility that were originally due to expire in July 2025. This lease termination resulted in a gain of $4,602, which is also included in income from discontinued operations in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2021.
After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), and Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), including the associated deferred revenue remaining under each collaboration agreement (Notes 4 and 5), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying condensed consolidated financial statements for all periods presented as a result of the Company's continuing involvement.
There were no discontinued operations related to MBP Titan for the three months ended March 31, 2022. The following table presents the financial results of discontinued operations related to MBP Titan for the three months ended March 31, 2021:
Three Months Ended 
 March 31,
2021
Operating gains$4,526 
Operating income4,526 
Income before income taxes4,526 
Income from discontinued operations$4,526 

14

Table of Contents
The following table presents the significant noncash items, purchases of property, plant and equipment, and proceeds from sales of assets for the discontinued operations related to MBP Titan for the three months ended March 31, 2021 that are included in the accompanying condensed consolidated statements of cash flows.
Three Months Ended 
 March 31,
2021
Adjustments to reconcile net loss to net cash used in operating activities
Gain on disposals of assets, net$(464)
Noncash gain on termination of leases(4,602)
Cash flows from investing activities
Proceeds from sales of assets1,083 

4. Investments in Joint Ventures
Intrexon Energy Partners
In 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, a JV formed to optimize and scale-up the Company's MBP technology for the production of certain fuels and lubricants. The Company also entered into an exclusive channel collaboration ("ECC") with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of March 31, 2022, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.
The Company's investment in Intrexon Energy Partners was $(429) and $(428) as of March 31, 2022 and December 31, 2021, respectively, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners.
See Note 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners.
Intrexon Energy Partners II
In 2015, the Company and certain investors (the "IEPII Investors"), entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, a JV formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of March 31, 2022, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five
15

Table of Contents
members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.
The Company's investment in Intrexon Energy Partners II was $(435) as of March 31, 2022 and December 31, 2021, and is included in other accrued liabilities in the accompanying condensed consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II.
See Notes 3 and 16 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.
5. Collaboration and Licensing Revenue
Historically, the Company has derived collaboration and licensing revenue through agreements with counterparties for the development and commercialization of products enabled by the Company's technology platforms. These collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.
The Company recognizes the reimbursement payments received for research and development efforts in the period when the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services, and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services. The Company assesses the uncertainty of when and if any milestones will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved. Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC Topic 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.
The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation.
The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2022 and 2021.
 Three Months Ended 
 March 31,
20222021
Castle Creek Biosciences, Inc.$ $59 
Other 7 
Total (1)$ $66 
(1)Collaboration and licensing revenues include the recognition of $0 and $66 for the three months ended March 31, 2022 and 2021, respectively, associated with upfront and milestone payments which were previously deferred.
There have been no significant changes to the agreements with our collaborators and licensees in the three months ended March 31, 2022.
16

Table of Contents
Deferred Revenue
Deferred revenue primarily consists of upfront and milestone consideration received for the Company's collaboration and licensing agreements. Revenue is recognized as services are performed. The arrangements classified as long-term (of which $21,205 is related to agreements with Intrexon Energy Partners L.L.C. and Intrexon Energy Partners II, L.L.C.) are not active while the respective counterparties evaluate the status of the project and its desired future development activities since the Company cannot reasonably estimate the amount of service to be performed over the next year.
Deferred revenue consisted of the following:
March 31,
2022
December 31,
2021
Collaboration and licensing agreements$23,023 $23,023 
Prepaid product and service revenues2,511 4,229 
Other158 213 
Total$25,692 $27,465 
Current portion of deferred revenue$2,669 $4,442 
Long-term portion of deferred revenue23,023 23,023 
Total$25,692 $27,465 

6. Short-term and Long-term Investments
The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of March 31, 2022:
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate
Fair Value
U.S. government debt securities$102,771 $ $(1,133)$101,638 
Certificates of deposit97   97 
Total$102,868 $ $(1,133)$101,735 
The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2021:
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate
Fair Value
U.S. government debt securities$121,036 $ $(331)$120,705 
Certificates of deposit97   97 
Total$121,133 $ $(331)$120,802 
The estimated fair value of available-for-sale investments classified by their contractual maturities as of March 31, 2022 was:
Due within one year$71,821 
After one year through two years29,914 
Total$101,735 
Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. We do not intend to sell these investments and nor is it more likely than not that the Company will be required to sell these investments, prior to maturity or recovery of amortized cost.
17

Table of Contents
7. Fair Value Measurements
The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.
Assets
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of March 31, 2022:
Quoted Prices in Active Markets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
March 31,
2022
Assets
U.S. government debt securities$ $101,638 $ $101,638 
Certificates of deposit 97  97 
Total$ $101,735 $ $101,735 
The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2021:
Quoted Prices in Active Markets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
December 31,
2021
Assets
U.S. government debt securities$ $120,705 $ $120,705 
Certificates of deposit 97  97 
Total$ $120,802 $ $120,802 
The method used to estimate the fair value of the Level 2 short-term and long-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets.
Liabilities
The carrying values of the Company's long-term debt, excluding the 3.50% convertible senior notes due 2023 (the "Convertible Notes"), approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.
The calculated fair value of the Convertible Notes (Note 11) was approximately $164,000 and $160,000 as of March 31, 2022 and December 31, 2021, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying condensed consolidated balance sheets at amortized cost, which was $198,362 and $179,882 as of March 31, 2022 and December 31, 2021, respectively (see Note 2 regarding adoption of ASU 2020-06 on January 1, 2022).
18


8. Inventory
Inventory consists of the following:
March 31,
2022
December 31,
2021
Supplies, embryos and other production materials$2,931 $2,588 
Work in process2,539 2,564 
Livestock5,918 6,310 
Feed1,342 1,799 
Total inventory$12,730 $13,261 
9. Property, Plant and Equipment, Net
Property, plant and equipment consist of the following:
March 31,
2022
December 31,
2021
Land and land improvements$11,118 $11,118 
Buildings and building improvements12,903 12,896 
Furniture and fixtures1,193 1,162 
Equipment34,304 33,584 
Leasehold improvements4,822 4,822 
Breeding stock953 1,000 
Computer hardware and software5,169 5,131 
Construction and other assets in progress3,596 3,824 
74,058 73,537 
Less: Accumulated depreciation and amortization(40,475)(39,222)
Property, plant and equipment, net$33,583 $34,315 
Depreciation expense was $1,483 and $1,593 for the three months ended March 31, 2022 and 2021, respectively.
10. Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for the three months ended March 31, 2022 were as follows:
Balance at December 31, 2021$54,148 
Impairment(482)
Foreign currency translation adjustments(53)
Balance at March 31, 2022$53,613 
The Company recorded $482 of goodwill impairment related to the total goodwill assigned to one reporting unit within the biopharmaceutical segment during the first quarter of 2022.
The Company had $44,125 and $43,643 of cumulative impairment losses as of March 31, 2022 and December 31, 2021, respectively.
19

Table of Contents
Intangible assets consist of the following as of March 31, 2022:
Gross Carrying AmountAccumulated AmortizationNet
Patents, developed technologies and know-how$90,000 $(39,595)$50,405 
Customer relationships10,850 (10,480)370 
Trademarks5,900 (5,248)652 
Total$106,750 $(55,323)$51,427 
Intangible assets consist of the following as of December 31, 2021:
Gross Carrying AmountAccumulated AmortizationNet
Patents, developed technologies and know-how$91,373 $(38,630)$52,743 
Customer relationships10,850 (10,252)598 
Trademarks5,900 (5,126)774 
Total$108,123 $(54,008)$54,115 
Amortization expense was $1,809 and $1,930 for the three months ended March 31, 2022 and 2021, respectively.
11. Lines of Credit and Long-Term Debt
Lines of Credit
Trans Ova had a $5,000 revolving line of credit with First National Bank of Omaha that matured on April 1, 2022. The line of credit bore interest at the greater of the U.S. Prime Rate or 3.00%, and the actual rate was 3.50% as of March 31, 2022. As of March 31, 2022 and December 31, 2021, there was no outstanding balance. The amount available under the line of credit was based on eligible accounts receivable and inventory up to the maximum principal amount and was $5,000 as of March 31, 2022.
Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2022. As of March 31, 2022, the line of credit bore interest at a stated rate of 4.00% per annum. As of March 31, 2022 and December 31, 2021, there was no outstanding balance.
Long-Term Debt
Long-term debt consists of the following:
March 31,
2022
December 31,
2021
Convertible debt (1)$198,362 $179,882 
Notes payable3,105 3,217 
Other 52 
Long-term debt201,467 183,151 
Less current portion355 402 
Long-term debt, less current portion$201,112 $182,749 
20


(1)See Note 2 regarding adoption of ASU 2020-06 as of January 1, 2022.
Convertible Debt
Precigen Convertible Notes
In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042.
The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:
During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or
Upon the occurrence of specified corporate events as defined in the Indenture.
None of the above events allowing for conversion prior to April 1, 2023 occurred during the three months ended March 31, 2022. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date.
If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.
The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount.

As described in Note 2, the Company adopted ASU 2020-06 on January 1, 2022. Pursuant to ASU 2020-06, the equity components of the Convertible Notes separated from the debt components as required under the cash conversion model is required to be recombined into the Convertible Notes as a single instrument upon the adoption of ASU 2020-06. The
21


Convertible Notes shall be accounted for as if the conversion option had not been separated. As the Company elected the modified retrospective approach, the difference between the accounting under the cash conversion model and new model after the adoption of ASU 2020-06 (i.e., the single debt instrument with no separation) was recorded as an adjustment on the adoption date (i.e., January 1, 2022) through accumulated deficit. Tax accounting consequences of the adoption also required the reversal of the previously reported deferred tax benefit on the date of adoption.

Adoption of ASU 2020-06 resulted in an increase to long-term debt outstanding, net of current portion, of $18,196, a decrease to additional paid-in capital of $36,868, and a decrease to accumulated deficit of $18,672. Interest expense recognized on the convertible notes in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost.

As of March 31, 2022, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $198,362. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 4.25%. As of March 31, 2022, the unamortized long-term debt discount and debt issuance costs totaled $1,638.
The components of interest expense related to the Convertible Notes were as follows:
 Three Months Ended 
 March 31,
 20222021
Cash interest expense$1,750 $1,750 
Non-cash interest expense284 2,751 
Total interest expense$2,034 $4,501 
Accrued interest of $1,750 is included in other accrued liabilities on the accompanying condensed consolidated balance sheet as of March 31, 2022.
Notes Payable
Trans Ova has a note payable that matures in April 2033 and had an outstanding principal balance of $3,105 as of March 31, 2022. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.
Future Maturities
Future maturities of long-term debt as of March 31, 2022 are as follows:
2022$265 
2023200,365 
2024380 
2025395 
2026411 
2027428 
Thereafter861 
Total$203,105 
12. Income Taxes
Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. The Company has U.S. taxable loss of approximately $5,300 and $40,400 for the three months ended March 31, 2022 and 2021, respectively. The following table presents the components of income tax benefit from continuing operations.
22


 Three Months Ended 
 March 31,
 20222021
Current foreign income tax expense from continuing operations$ $4